Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Recordati Industria Chimica e Farmaceutica Global pharma group developing drugs for common/rare diseases & supplying APIs worldwide.	Italy	REC
RECURSION PHARMACEUTICALS, INC. AI-driven biotech accelerating drug discovery for rare diseases and oncology.	United States of America	RXRX
RedHill Biopharma Ltd. Develops oral drugs for GI, infectious diseases, and pandemic preparedness.	United States of America	RDHL
Regencell Bioscience Holdings Ltd Develops TCM-based therapies for neurocognitive disorders like ADHD and ASD.	United States of America	RGC
REGENERON PHARMACEUTICALS, INC. A biotech firm inventing, developing, and commercializing medicines for serious diseases.	United States of America	REGN
REGENXBIO Inc. Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.	United States of America	RGNX
Rein Therapeutics, Inc. Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.	United States of America	RNTX
Rekah Pharmaceutical Prod Ltd. A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.	Israel	REKA
Relay Therapeutics, Inc. Developing precision medicines for oncology & genetic diseases by analyzing protein motion.	United States of America	RLAY
Repare Therapeutics Inc. Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.	United States of America	RPTX